Клиническое и патогенетическое значение провоспалительныхитокинов и антител к коллагену при хронической сердечной недостаточности
Диссертация
Впервые проведено комплексное исследование содержания провоспалительных цитокинов и антител к коллагену у больных ХСН, оценено их содержание при отдельных нозологических формах, являющихся причинами развития сердечной недостаточности. Показано, что при заболеваниях, являющихся причиной развития ХСН, имеется повышение уровня провоспалительных цитокинов и антител к коллагену, что приводит… Читать ещё >
Список литературы
- Агеев Ф.Т., Овчинников А. Г., Сербул В. М., Беленков Ю. Н. Гипертрофия левого желудочка: роль ренин-ангиотензиновой системы // Сердечная недостаточность.-2008.-№ 1.-С. 16−25.
- Агеев Ф.Т., Овчинников А. Г. Диастолическая дисфункция как проявление ремоделирования сердца// Сердечная недостаточность.-2002.-№ 4.-С. 190 196.
- Беленков Ю.Н., Мареев В. Ю. Принципы рационального лечения сердечной недостаточности.- М., 2001, 264с.
- Беленков Ю.Н. Ремоделирование левого желудочка: комплексный подход//Сердечная недостаточность.- 2002, — № 4, С. 161 -163
- Беленков Ю.Н., Агеев Ф. Т., Мареев В. Ю. Нейрогормоны и цитокины при сердечной недостаточности: теория старого заболевания? //Сердечная недостаточность.-2000.-№ 4.-С. 135−138.
- Беленков Ю.Н., Овчинников А. Г. Должны ли мы лечить диастолическую сердечную недостаточность так же, как и систолическую // Сердечная недостаточность.-2004, — № 4.- С.116−122.
- Богова О. Т. Инфаркт миокарда. Воспаление и прогноз // Рос. кардиол. журн.-2003.-№ 4.-37−42.
- Бороздюля М.Э., Вахрамеева Н. В., Шляхто Е. В. и др. Влияние ингибиторов АПФ на цитокиновую активацию и дисфункцию эндотелия у больных хронической сердечной недостаточностью // Сердечная недостаточность.-2001-№ 4,-С.62−64
- Васюк Ю.А., АтрощенкоЕ.С., Ющук E.H. Плейотропные эффекты статинов данные фундаментальных исследований //Сердце.- 2006.-№ 5, С.228−236
- Восканьянц А. Н., В. А. Нагорнев. Пролиферация клеток стенки артерий человека при атерогенезе как фактор проявления иммунного воспаления // Цитокины и воспаление. 2004. — Т. 3, № 4. — 10−13.
- Гланц С. Медико-биологическая статистика // М: Практика,-1999, -459с.
- Грацианский H.A. Нестабильная стенокардия — острый коронарный синдром. Современное состояние проблемы лечения //Кардиология.-1997. -№ 1.-С. 8−23.
- Демьянов А. В., Котов А. Ю. Диагностическая ценность исследования уровней цитокинов в клинической практике // Цитокины и воспаление. -2003.-Т. 2, № 3.-20−35.
- Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр) Разработаны Комитетом экспертов Всероссийского научного общества кардиологов
- Гусев Е. Ю., Юрченко Л. Н., Черешнев В. А. Методология изучения системного воспаления // Цитокины и воспаление. 2008. — Т. 7, № 1. -15−23.
- Деримедведь В.Д., Губина-Вакулик Г.И., Деримедведь Л. В. Клинические и иммунологические сопоставления при инфаркте миокарда // Вестник научных исследований. 1995. — № 5. — С. 12−16.
- Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр). Разработаны Комитетом экспертов ВНОК.- М. 2008.
- Диагностика и лечение внутренних болезней: руководство для врачей в 3 т. /Под общей ред. Ф. И. Комарова. Т. 1. Болезни сердечно-сосудистой системы, ревматические болезни / Под ред. Е. Е. Гогина. М: Медицина, 1996. — 560 с.
- Добровольский А.Б., Панченко Е. П., Карпов Ю. А. Роль компонентов системы фибринолиза в атеротромбогенезе // Кардиология. 1996. — № 5. — С. 68−71.
- Дубов П.Б., Коняева Е. Б., Остроумов E.H., Сергиенко В. Б., Юренев А. П. Гипертоническая болезнь и «немая» ишемия миокарда. Сообщение I. Результаты нагрузочной сцинтиграфии миокарда у больных //Тер.архив, 1992, № 4, с. 9−11.
- Дубов П.Б., Фофанова Т. В., Остроумов E.H., Юренев А. П. Миокардиальный резерв перфузии и гипертрофия миокарда у больных гипертонической болезнью и «немой» ишемией миокарда. // Кардиология, 1994, № 6, с. 126−128.
- Закирова AJL, Мухаметрахимова АР., Закирова Н. Э. Состояние систолической функции левого желудочка и активность провоспалительных цитокинов при остром инфаркте миокарда // Сердечная недостаточность. -2005. -Т.6, № 4. С. 162−164.
- Карпов Ю.А. Ингибиторы АПФ: от снижения артериального давления до профилактики осложнений и улучшения прогноза // Сердечная недостаточность. -2002. № 4. — С. 192−196.
- Карпов P.C., Дудко В. А. Атеросклероз. Томск: STT, 1998. — 656 с.
- Карпов P.C., Павлкжова E.H., Мордовии В. Ф., Трисветова Е. П., и др. Изучение перфузии миокарда у больных гипертонической болезнью // Кардиология, 1992, № 3, с. 40−42.
- Кевра М.К. Гемодинамические эффекты фактора некроза опухолей // Фамакологические свойства новых химических соединений и некоторых лекарственных препаратов: Материалы конф. Минск, 1994. — С. 101.
- Климов А.Н. Иммунореактивность и атеросклероз -Л.: Медицина, 1986.192 с.
- Климов А.Н. Аутоиммунная теория патогенеза и концепция модифицированных липопротеидов // Вест. АМН СССР. 1990. — № 11. — С. 3036.
- Климов А.Н., Нагорнев В. А. Взгляд на решение проблемы атеросклероза // Вест. Рос. АМН. 1999. — № 9. — С. 33−37.
- Климов А.Н., Никульчева Н. Г. Липиды, липопротеиды и атеросклероз. -СПб.: Питер Пресс, 1995. 304 с.
- Козлов В. А. Некоторые аспекты проблемы цитокинов. //Цитокины и воспаление.-2002.-т. 1 .-№ 1 .-С.5−8
- Ласкин С.А., Жаров Е. И., Лифшиц Г. Я., и др. Влияние артериальной гипертонии на состояние миокарда левого желудочка по данным сцинтиграфии миокарда с 201-Т1 //Кардиология, 1989, № 10, с.93−96.
- Лопатин Ю.М., Илюхин О. В., Илюхина М. В., Иваненко В. В. Эластичность артерий и скорость пульсовой волны у больных различной сердечной недостаточностью различной этиологии // Сердечная недостаточность. -2004.- Том 5. № 4. 130−131.
- Луговская С.А. Структура и функции моноцитов и макрофагов // Клиническая лабораторная диагностика. 1997. — № 9. — С. 10−16.
- Мазуров В.И., Столов СВ., Липецкая Н. Э. Динамика уровней провоспалительных цитокинов у больных в зависимости от различных форм ИБС //Клиническая медицина.-1999.-№ 11.-С.23−27
- Мареев В.Ю. Лечение хронической сердечной недостаточности. Время статинов?// Кардиология 2005.- том 45.-№ 12. 4−10
- Мареев В.Ю. Рекомендации по рациональному лечению больных с сердечной недостаточностью // Consilium medicum. 1999. — № 3. — С. 109−146.
- Нагорнев В.А. Атерогенез и иммунное воспаление // Архив патологии. -1995.-№ 3.-С. 6−14.
- Нагорнев В.А., Кетлинский С. А. Клеточно-молекулярные механизмы становления и развития атерогенеза (CD40-CD40L иммунорегуляторный сигнал) // Бюл. экспер. биол. 1999. — № 10. — С. 364−371.
- Насонов Е.Л., Самсонов М. Ю., Беленков Ю. Н. и др. Иммунопатология застойной сердечной недостаточности: роль цитокинов // Кардиология. 1999.-№ 3.-С. 66−73.
- Насонов Е.Л., Пашкова Е. В., Александрова Е. Н. С-реактивный белок и маркеры воспаления при атеросклерозе // Кардиология 2002.- № 7.5362.
- Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр) // Сердечная недостаточность. -2007. № 1. -С.4−42.
- Недогода СВ., Чаляби Т. А., Цома В. В., Брель У. А. Аторвастатин и улучшение эластичности сосудов при гиперлипидемии // Болезни сердца и сосудов.- 2007. № 1. -С. 33−36.
- Никитина Е.Ю., Мальцева СВ., Чураков Г. А. и др. Влияние нативных липопротеинов низкой плотности на продукцию цитокинов клетками линий P38D1 и ECV304 // Иммунология. 1998. — № 6. — С. 20.
- Оганов Р.Г. Факторы риска атеросклероза и ишемической болезни сердца. Вопросы профилактики // Болезни сердца и сосудов: Руководство/Под ред. Е. И. Чазова. М.: Медицина, 1992. — Т. 2. — С. 155 -177.
- Огурцов Р.П., Пигаревский П. В., Сергеева Е. Г. и др. Особенности синтеза фактора некроза опухоли в условиях гиперлипидемии // Иммунология-1998.- № 6.- С. 20.
- Озова Е.М. Воспалительно-метаболический профиль, эластические свойства сосудов у больных с хронической сердечной недостаточностью и низкой фракцией выброса. Эффекты карведилола и аторвастатина // Дис. канд. мед. наук. 2008
- Ольбинская JI. И., Игнатенко С. Б. Роль цитокиновой агрессии в патогенезе синдрома сердечной кахексии у больных с сердечной недостаточностью // Сердечная недостаточность. -2001. № 3. -С.58−64.
- Ольбинская Л.И., Игнатенко СБ. Роль цитокинов в патогенезе хронической сердечной недостаточности // Тер.архив.-2001 .-№ 12. -С.82−84
- Орлова Я.А., Агеев Ф. Т. Жесткость артерий как интегральный показатель сердечно-сосудистого риска: физиология, методы оценки и медикаментозной коррекции // Сердечная недостаточность. -2006. № 2. -С.65−70.
- Павликова Е.П., Мерай И. А. Клиническое значение интерлейкина-6 и фактора некроза опухоли при ишемической болезни сердца // Кардиология. -2003. -№ 8. С.68−71.
- Пальцев М.А. Цитокины и их роль в межклеточных взаимодействиях //Арх. Пат. -1996. т. 58. — № 6. — С. 1−6.
- Пальцев М.А., Иванов A.A. Межклеточные взаимодействия М.: Медицина, 1995, 175с.
- Рыбакова М.Г., Кузнецова И. А. Роль апоптоза в ишемическом повреждении миокарда // Арх. патологии. -2005. -Т.65, № 5. -С.23−25.
- Российские национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН, 2 пересмотр, 2006 // Сердечная Недостаточность.- Том 12.- С. 52−78.
- Семенов В. Н, Пасечник И. Н. Апоптоз и его роль в патогенезе критических состояний // Вестник интенсивной терапии. -2004. III, -С. 3−7.
- Сергеева Е.Г., Огурцов Р. П., Зиновьева H.A. и др. Туморнекротизирующий фактор и состояние иммунореакгивности у больных ишемической болезнью // Кардиология. 1999. — № 3. — С. 26−28.
- Сергиенко В.Б., Саютина Е. В., Самойленко JI.E. и др. Роль дисфункции эндотелия в развитии ишемии миокарда у больных ишемической болезнью сердца с неизмененными и малоизмененными коронарными артериями // Кардиология. 1999. -№ 1.- С. 16−18.
- Серов В.В., Шехтер А. Б. Соединительная ткань. М.:Медицина, 1981.
- Симбирцев А. С., Цитокины: классификация и биологические функции // Цитокины и воспаление. 2004. — Т. 3, №. 2. — С. 16−22.
- Симбирцев A.C., Цитокины — новая система регуляции защитных реакций организма // Цитокины и воспаление. 2002. — Т. 5, № 1. — С.27−32.
- Сгорожаков Г. И. Внезапная сердечная смерть // Сердце. 2007. — Т.6, № 3. — С.156−163.
- Сгорожаков Г. И, Утешев Д. Б. Роль апоптоза в развитии атеросклероза, ишемии миокарда, сердечной недостаточности // Сердечная недостаточность. 2000. — Т1, № 4. -С.60−64.
- Сумароков A.B. Ишемическая болезнь и начальный атеросклероз экстракраниальных сосудов //Кардиология. 1996. — № 12. — С. 79−89.
- Сумароков A.B., Моисеев B.C. Клиническая кардиология. М: Универсум паблишинг, 1995. 238 с.
- Суркина И.Д., Степура ОБ., Пак JI.C. и др. Иммунно-интерфероноваясистема и сердечно-сосудистые заболевания // Кардиология. 1999. — № 4. -С. 59−62.
- Сысоев К.А., Калинина Н. М. Продукция ИЛ-6 и ФНО-а in vivo и in vitro у пациентов с сердечно-сосудистой патологией // Медицинская иммунология. 1999.-Т. 1.- № 3−4.-С.88−92.
- Титов Н.В. Лабораторные методы исследования в кардиологии // Болезни сердца и сосудов: Рук-во для врачей /Под ред. Е. И. Чазова М.: Медицина, 1992.- Т.1.- С.464−481.
- Фабричников С.В., Фабричникова Н. И., Митрейкин В. Ф. и др. Цитокины и их роль в развитии типовых патологических процессов. Пособие.-2000,115с.
- Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология. Основы доказательной медицины: Пер. с англ. М: Медиа Сфера, 1998. -352с.
- Флоря В.Г., Беленков Ю. Н. Ремоделирование сосудов, как патогенетический компонент заболеваний сердечно-сосудистой системы //Кардиология, 1989, № 12, стр. 72−78.
- Фомин И.В., Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации — данные ЭПОХА-ХСН // Сердечная недостаточность. -2006. № 3. — С. 112−116.
- Фрейдлин И.С. Иммунная система и ее дефекты: Руководство для врачей. СПб.- 1998.- 113 с.
- Шахнович РМ., Басинкевич АБ. Маркеры воспаления и ОКС // Кардиология СНГ. 2005.-№ 3.-С.58−64.
- Шерстобоев Е. Ю. Бабаенко А.П. Модуляция выработки цитокинов адреномиметиками на фоне стресса и антигенного воздействия // Цитокины и воспаление. 2007. — Т. 6, № 3. — 40−43.
- Шехтер А.Б., Серов В. В. Воспаление, адаптивная реакция и дисрегенерация (анализ межклеточных взаимодействий) //Арх.пат.-1991.-№ 7 С.7−14.
- Ярилин A.A. Система цитокинов и принципы ее функционирования в нормеи при патологии// Иммунология. 1997. — № 5. — С. 7−13.
- Achenbach S, Ropers D, Pahle К, et al.- Influence of lipid-lowering therapy on progress of coronary artery calcification// Circulation 2002- 106: 1077−82.
- Ahsan CH, Shah A, Ezekowitz M. Acute statin treatment in reducing risk after acute coronary syndrome: the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial. // Curr Opin Cardiol. 2001−16 (6):390−393.
- Aikawa M., Rabkin E., Sugiyama S. et al. An HMG-Co reductase inhibitor cerivastatin, suppresses growth of macrophages, expressing matrix metalloproteinases and tissue factor in vivo and in vitro. // Circulation .-2001.-Vol. 103(2).-P. 276−283.
- Amberger A., Maczek C, Jurgens G. et al. Co-expression of ICAM-1, VCAM-1, ELAM-1 and Hsp-60 in human arterial and venous endothelial cells in response to cytokines and oxidized low-density lipoproteins // Cell Stress Chaperones. -1997 Vol.2. -P.94−103.
- Ambrosi P., Bruneau P., Faugere G., Habib G., Poggi L., Luccioni R., Bernard PJ. Prognostic value of thallium-201 myocardial scintigraphy in patients with hypertension, suspected of coronary disease. //Ann.Cardiol.Angeiol. (Paris), 1993- 42(9):479−483.
- Amento E.P., Ehsani R, Palmer H. et al. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells // Arterioscler. Thromb. 1991. — Vol. 11. -P. 1223−1230.
- Anker S.D., von Haehling S. Inflammatory mediators in chronic heart failure: an overview // Heart. 2004. Vol.90. P. 464−470.
- Anker SD, Negassa A, Coats AJ et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensinconvertingenzyme inhibitors: an observational study // Lancet- 2003.-Vol. 361,-P. 10 771 083.
- Anker S.D., Coats A.J. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH Int J Cardiol.- 2002.- Vol. 86.- P. 123−30.
- Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their immunogenicity profiles. // Semin. Arthr. Rheum., 2005, v.34, suppl. I, p. 1922.
- Andonopoulos A.P., Meimaris N., Daoussis D. et al. Experience with infliximab as monotherapy for giant cell arteritis. Ann. Rheum.Dis., 2003, v.62, p. l 116.
- Anguera I., Bosch X., Filella X. et al. Higher plasma levels of tumor necrosis factor, interleukin-2 soluble receptor in patients with unstable angina pectoris and poor clinical evolution (Abstr.) // Eur. Heart J. -1998. Vol. 19. — P. 170.
- Arnaud C Mach F. Pleiotropic effects of statins in atherosclerosis. Role on endothelial function, inflammation and immunomodulation // Arch Mai Coeur.-2005.-Vol. 98, P. 661−663.
- Athanasios G. Kontopoulos, Vasilios G. et al Long-Tenn Treatment Effect of Atorvastatin on Aortic Stiffness in Hypercholesterolaemic Patients // Curr Med Res 0pin.-2003.- Vol. 19.-N 1.- P.22−27.
- Aukrust P., Ueland T., Lien E. The cytokine network in congestive heart failure: disbalance between proinflammatory mediators (Abstr.) // Eur. Heart J. 1998. -Vol. 19.- P. 170.
- BachettiT., Comini L., Pasini E., Ferrari R. Anti-cytokine therapy in chronic heart failure: new approaches and unmet promises // Eur Heart J.- 2004.- N 6.- P. 16−22.
- Banchereau J. Paczesny S., Dendritic C., Blanco P. et al Cells controllers of the immune system and a new promise for immunotherapy // Ann N. Y. Acad. Sci.-2003.-Vol. 987.-P. 180−187.
- Barnard J.A., Lyons R. M., Moses H.L. The cell biology of transforming growth factor-beta // Biochem. biophys. Acta. 1990. — Vol.1032.- P.79−87.
- Barr S.G., Steber W., Kindopp-Bugo K., Martin O.L. Infliximab therapy in the treatment of rheumatoid arthritis in clinical practice. Ann.Rheum. Dis., 2003, v.62, suppl. l, p. 196.
- Basaran Y., Basaran M.M., Babacan K.F. Serum tumor necrosis factor levels in acute myocardial infarction and unstable angina pectoris // Angiology. 1993. -Vol.44. -P.332−337.
- Bath P.M. W., Mayston S.A., Martin J.F. Endothelin and PDGF do not stimulated periferal blood monocyte chemotaxis, adhesion to endothelium, and superoxide production//Exp. Cell. Res. 1990. — Vol. 187. — P. 339 345.
- Beevor C.P., Hull R., Thomas A. et al. Anti TNFa therapy reduces emergency health services usage. Ann. Rheum. Dis., 2006, v.65, suppl. II, p. 176.
- Bendtzen K. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity//Immunol. Lett. 1988. — Vol. 19. -P.183−192.
- Bevilacqua M. Endothelial-leucocyte adhesion molecules // Ann. Rev. Immunol. 1993. — Vol. 11. — P. 767−804.
- Biasucci L.M., Liuzzo G., Grillo R.L. et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability // Circulation. 1999. -Vol. 99. — P.855−860.
- Bimer C.M., Ulucan C., Fredersdorf S. et al. Head-to-head comparison of BNP and IL-6 as markers of clinical and experimental heart failure: Superiority of BNP. //Cytokine.- 2007.-Vol.40(2).-P.89−97.
- Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med. 2001 -110 (9):716−723.
- Blacher J., Asmar R., Djane S., et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients Hypertension.- 1999.-Vol. 33.P.1111−7.
- Blake G.J., Ridker P.M. Are statins anti-inflammatory? //Curr Control Trials Cardiovasc Med. 2000. Vol. 1P 161−165.
- Blankerberg S., Rupprecht H. J. Cytomegalovirus infection-with interleukin-6 response predicts cardic mortality in patients with coronary artery disease // Circulation. 2001. — Vol. 103. — P. 2915−2921.
- Blum A., Miller H. Role of cytokines in heart failure//Am. Heart J. 1998. -Vol. 135.- P.181−186.
- Boden W. E, Orourke R. A., Teo K.K., et al., for the COURAGE Trial Research Group Optimal Medical Therapy with or without PCI for Stable Coronary Disease //N.Engl. J. Med. -2007.-VoI.356.-№ 15.-P.1503-I516.
- Bohm M., Hjalmarson A., Kjekshus J., Laufs U. Heart failure and statins why do we need a clinical trial? // Z Kardiol. 2005.-Vol. 94.-P.223−30.
- Bolger A.P., Anker S.D. Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications // Drugs.- 2000.- Vol. 60.-P. 1245−57.
- Boisvert W.A., Santiago R., Curtiss L.K. et al. A leucocyte Homologue of the IL-8 reseptor CXCR -2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor -deficient mice // J Clin Invest. -1998, -101, -P.353−363.
- Bonta I.L., Ben-Efraim S. Interactions between inflammatory mediators in expression of antitumor cytostatic activity of macrophages // Immunol. Lett. 1990. Vol. 25. — P. 295−302.
- Booth A., Harper L., Hammad T. et al. Prospective study of TNF-CX blockade with infliximab in anti-neutrophil cytoplasmic antibody-asso^ciated systemic vasculitis // J.Amer.Soc.Nephrol., 2004, v. 15, p.717−721.
- Boring L., Gosling J., Cleary M. et al. Decreased lesion formation in CCR2 mice reveals a role for chemokines in the initiation of atherosclerosis // Nature. 1998. -Vol. 394.-P.894−897.
- Bourcier T., Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor -1 expression by human vascular smooth muscle and endothelial cells 11 Arterioscler. Thromb. Vase. Biol. 2000. — V.20. — R556−562.
- Bozkurt B. Activation of cytokines as a mechanism of disease progression in heart failure Ann Rheum Dis.- 2000.- Vol. 59(suppl I).-P. i90-i93.
- Boyle J., Bennett M., Proudfoot D. et al. Humane monocyte/macrophages induce human vascular smooth muscle cell apoptosis in culture (Abstr.) // J. Pathol.-1998.-Vol. 184.-P. 13.
- Braun M., Pietsch P., Felix S.B. Modulation of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 on human coronary smooth muscle cells by cytokines // J. Mol. Cell. Cardiol. -1995. Vol. 27. -P.2571−2579.
- Braun-Dullaeus R.C., Mann M.J., Dzau V.J. Cell cycle progression: new therapeutic target for vascular proliferate disease // Circulation. 1998−98(l):82−89.
- Brilla C.G., Maisch B., Weber K.T. Myocardial collagen matrix remodelling in arterial hypertension. // Eur. Heart J., 1992- 13 Suppl D: 24
- Bruijn J. A., Hogendoom P. C. W., Hoedemaeker P. J., Fleuren G. J. The extracellular matrix in pathology // J. Lab. clin. Med.-1988.-Vol. 111. -P.140−149.
- Buffon A., Liuzzo G., Biasucci L.M. et al. Neutrophil activation in the coronary tree of unstable angina patients is not related to site of coronary stenosis or to ischaemia-reperfusion injury // Eur Heart J. 1996. — Vol. 17. -P. 349.
- Bussolino F., Breviario F., Jetta C et al. Interleukin-1 stimulates platelet-activating factor production in cultured human endothelial cells // J. Clin. Invest. -1986. Vol. 77. -P. 2027−2033.
- Butcher E.C. Cellular and molecular mechanisms that direct leucocyte traffic // Amer. J. Path.-1990.-Vol. 136.- P. 3−12.
- Cannon C.P., McCabe C.H., Belder R., Breen X., Braunwald E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE rT)-T1M122 trial//Am. J. Cardiol. -2002. -Vol.89.-№ 7. -P.860−861.
- Cantin B., Despres J.P., Lamarche A. et al. Association of fibrinogen and lipoprotein (a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol. 2002−89 (6):662−666.
- Carson P.A., Ribeiro J.M. Apoptosis and disease //Lancet-1993.- Vol. 341. P. 1251−1254.
- Carvalho A.C., Colman R.W., Lees R.S. Platelet function in hyperlipoproteinemi. N Engl J Med. 1974−290 (8):34−438.
- Chin W.L., O’Kelly B., Tubau J.F., Szlachcic J. Diagnostic accuracy of exercise thallium-201 scintigraphy in men with asymptomatic essential hypertension // Am.J.Hypertens., 1992−5(7):465−472.
- Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998−98 (9):839−844.
- Choussat R., Monnet X., Montalescot G. Inflammation and chronic infections in unstable coronary artery disease (Abstr.) // Eur. Heart J. 1998. -Vol. 19.1. P. 506.
- Chwartz R, Osborne-Lawrence S, Hahner L et al. C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. // Circ Res.-2007.-Vol. 100(10).-P. 1452−9.
- Clinton S.K., Libby P. Cytokines and growth factors in atherogenesis // Arch. Pathol. Lab. Med. -1992. Vol. 116. — P. 1292−1300.
- Cinquegrana G., DAniello L., Landi M., Spinelli L. Effects of different degrees of sympathetic antagonism on cytokine network in patients with ischemic dilated cardiomyopathy// J Card Fail.- 2005. Vol.ll.-N3.-P.213−9.
- Cleland J.G., Loh H., Windram J., Goode K., Clark A.L. Threats, opportunities, and statins in the modern management of heart failure Eur Heart J.- 2006.Vol. 27.-P.641−3.
- Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels // Circulation. 1998- 98 (9) — 83 9−844
- Conraads V.M., Bosmans J.M., Vrints C.J. Chronic heart failure: An example of a systemic chronic inflammatory. disease resulting in cachexia Int J CardioL2002.- Vol.85.- P.33−49.
- Conraads V. Pro-inflammatory cytokines and their receptors in chronic heart failure: do they really matter? //Acta Cardiol.-2006.-Vol. 61 (2).-P. 161−8
- Corsini A., Mazzotti M., Raiteriy M. et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase // Atherosclerosis. 1993−101(1): 117−125.
- Corsini A., Pazzucconi F., Pfister P. et al. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin // Lancet. 1996−348 (9041): 1584.
- Cronstein B.N., Weissmann G. The adhesion molecules of inflammation // Arthr. and Rheum.-1993.- Vol. 36. P. 147−157.
- Crouse J.R., Byigton R.P., Hoen H.M. et al. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med. 1997−157 (12):1305−1310.
- Cruickshank A.M., Oldroyd K.G., Cobbe S.M. Serum interleukin-6 in suspected myocardial infarction // Lancet. 1994. — Vol. 343. — P. 974.
- Cybulsky M. I., Gimbrone M. A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis // Science.- 1991.- Vol. 251.- P. 788−791.
- Danesh J., Collins R., Appleby P. et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease // J. Am. Med. Assoc. 1998. -Vol. 279. — P:1477−1482.
- Danesh J., Collins R., Peto R. Chronic infections and coronary heart disease: is there a link?//Lancet. 1997. — Vol. 350. — P. 430−436.
- Davies M. J. Stability and instability: two faces of coronary atherosclerosis // Circulation. 1996. -Vol. 94. — P.2013−2020.
- Davies M.J. Acute coronary thrombosis the role of plaque disruption and its initiation and prevention // Eur. Heart J. — 1995. — Vol. 16. — P. L3-L7.
- Davies M J., Richardson P.D., Woolf N. et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage and smooth muscle cell content // Br. Heart J. 1993. — Vol. 69. — P.377−381.
- De Caterina R., Peng H.R. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endotelian a expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995−96 (1):60—68.
- DeMaat M.P., Pietersma A., Kofflard M. et al. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatorymarkers//Atherosclerosis. 1996. -Vol. 121. — P. 185−191.
- Delerive P., Gervois P., Fruchart J., Staels B. Induction of IkBa expression as a mechanism contributing to the anti-inflammatory activities of peroxisome prolifeerator-activated receptor-a activators. //J Biol Chem.- 2000.-Vol. 275.-P. 36 703−36 707
- Deswal A., Petersen N.J., Feldman A.M. et al. Cytokines and cytokine receptors in advanced heart failure. An analysis of the cytokine database from vesnarinone trial (VEST)//Circulation.- 2001.-Vol. 103.-P.2055−9.
- Devereux R.B., Wachtell K., Gerdts E. et al. Prognostic significance of left ventricular mass change during treatment of hypertension// JAMA -2004. -Vol. 292. -№ 19.- P. 2350−2356.
- Dimitroulakos J., Nohynek D., Backway K.L. et al. Increased sensitivity of acute myeloid leukemia’s to lovastatin-induced apoptosis: a potential therapeutic approach.//Blood. 1999−93 (4):130S—1318.
- Dinarello C. A. Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases // Cur. Opin. Immunol.- 1991.- Vol. 3.- P. 941−948.
- Dinarello C. A. Interleukin-1 and interleukin-6 antagonism // Blood.— 1991.-Vol.77.-P. 1627−1652.
- Dinarello C.A. Biologic basis for interleukin-1 in disease // Blood. 1996. -Vol. 87.- P. 2095−2147.
- Dollery C.M., McEvan J.D., Henney A.M. Matrix metalloproteinase and cardiovascular disease // Circ. Res. 1995. — Vol. 77. — P.863−868.
- Downs J. R, Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS // JAMA. 1998−279 (20): 1615−1622.
- Drown D.J. Intercellular adhesion molecular IKAM-1 an emerging cardiovascular risk factor. // Prog Cardiovasc Nurs. 1998- 13 (4):30−33.
- Dupuis J. Mechanisms of acute coronary syndromes and the potential role of statins // Atheroscler Suppl. 2001, -2 (1):9−14.
- Eidelman R.S., Hermekerts C.H. Fibrinogen: a predictor of stroke and marker of atherosclerosis // Eur Heart J. 2003--24 (6):499-S00.
- El Sherif W.T., El Tooney L.F., Meki A.R., Abdel Moneim A. Proinflammatory cytokines, soluble Fas receptor, nitric oxide and angiotensin converting enzyme in congestive heart failure.// Egypt J Immunol.- 2005. Vol. 12(1). P.39−48.
- Emerson M., Momi S., Paul W. et al. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature. Thromb Haemost 1999−81 (6):961−966.
- Erdogan O., Ongen Z. The role of CRP and IL-6 in unstable angina // Circulation. 1997. — Vol. 6. — P. 2099−2101.
- Falk E., Shah P.K., Fuster V. Coronary plaque disruption//Circulation. -1995. -Vol.92. P. 657−671.
- Feige U., Campagnuolo G., Zhu L. et al. IL-l-beta and TNF-alpha produce divergent acute inflammatory and skeletal lesions in the knees of Lewis rats. Ann.Rheum.Dis., 2002, v.61, suppl. l, p.264−265.
- Feldmann M. Molecular mechanisms involved in human autoimmune diseases: relevance of chronic antigen presentation. Class II expression and cytokine production // Immunology.— 1989.— Vol. 19, Suppl. 2.— P. 6671.
- Feletar M., Brockbank J.E., Schentag C.T. et al. Treatment of refractory psoriatic arthritis with infliximab //Ann.Rheum.Dis., 2004, v.63, p.156−161.
- Feltelius N., Fored C.M., Blomqvist P. et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann.Rheum.Dis., 2005, v.64, p.246−252.
- Fernandes-Ortiz A., Badimon J.J., Falk E. et al. Chracterization of the relative thrombogenicity of atherosclerotic plaque components: implication for consequences of plaque rupture // J. Am. Coll. Cardiol. 1994. — Vol. 23. — P. 15 621 569.
- Ferrante A., Parinello A.G., Avellone G. et al. Atherosclerosis in females patients with rheumatoid arthritis- a two years follow-up. //Ann. Rheum. Dis., 2005, v.64, suppl. Ill, p.91.
- Ferreiros E., Boissonnet C., Merletti G. P. Elevated C-reactive protein at discharde is a strong independent predictor of 30-day outcome in unstable angina // Eur. Heart J. -1998. Vol. 19. Abstr. Suppl. — P. 138.
- Ferricr K. L, Mulilmann M., Baguer J. et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertion // JACC 2002- 34: 1020−5.
- Ferketich A.K., Ferguson J.P., Binklev P.F. Depression symptoms and inflammation among heart failure patients // Am Heart J. 2005.-Vol.150(1).-P. 132−6
- Forster C., Clark H.B., Ross N.E. Inducible nitric oxide synthase expression in humancerebral infarcts // Acta Neuropathol (Berl). 1999−97 (3):215−220.
- Fuster V., Badimon L., Badimon J.J. et al. The pathogenesis of coronary artery disease and the acute coronary syndromes // N. Engl. J. Med. 1992. — Vol. 326. -P.310−318.
- Fukumoto Y., Libby P., Rabkin E., Hill C et al. Statines alter smooth muscle accumulation and collagen content in established atheroma of Watanabe heriablehyperlipidemic rabbits. //Circulation.- 2001. -VoU03(7).-P. 993−999
- Fuster V., Fayad Z., Badimon J. Acute coronary syndromes: biology // Lancet. -1999. -Vol.353. P. 5−9.
- Fuster V., Lewis A. Mechanisms leading to myocardial infarction: insights from studies of vascular biology//Circulation. 1994. -Vol. 90. -P. 2126−2146.
- Gauthier T.W., Scans R., Murohara T. et al. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolema Arteriosder Thromb Vase BioL1995−15 (10):1652—1659.
- Geng Y., Libby P. Evidence for apoptosis in advanced human atheroma//Am. J. Pathol. 1995. — Vol. 147. — P. 251−266.
- Geng Y., Wu Q., Muszynski M. et al. Apoptosis of vascular smooth-muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor alpha and interleukin-l-beta // Arterioscler. Thromb. Vase. Biol. 1996. -Vol. 16. — P. 19−27.
- Geppert T.D., Davis L.S., Gur H. et al. Accessory cell signals involved in T-cell activation // Immunol. Rev.—1990.—Vol. 117.—P. 1−66.
- Gertz S.D., Roberts W.C. Hemodynamic shear force in rupture of coronary arterial atherosclerotic plaques // Am. J. Cardiol. 1990. — Vol. 66. — P. 1368−1372.
- Gotsman I., Stabholz A., Planer D. et al. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? // Med' Assoc J. 2008−10(7):494−8.
- Greig D., Castro P., Gabrielli L. et al. Inflammation and endothelial dysfunction in patients with chronic heart failure. //Rev Med Chil. 2008−1.36(6):687−93.
- Gori A.M., Bruneiii G., Pepe G. et al. Increased cytokine production in ischaemic heart disease patients (Abstr.) // Eur. Heart J. 1998. -Vol. 19. — P. 506.
- Grainger D.J., Kemp P.R., Metcalfe J.C. et al. The serum concentration of active transforming growth factor-p in severly depressed in advanced atherosclerosis //Nat. Med. 1995. — Vol. 1. — P.74−79.
- Gronholdt M-L. M., Dalager-Pedersen S., Falk E. Coronary atherosclerosis: determinants of plaque rupture // Eur Heart Journal. 1998. — Vol. 19. — P. C24-C29.
- Gullestad L., Aukrust P., Ueland T. et al. Effect of high as low dose ofenalapril therapy on cytokines levels in heart failure (Abstr.) // Eur. Heart J. 1998. -Vol. 19.-P. 468.
- Gullestad L., Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches // Am J Cardiol. 2005.-Vol. 95(UA).- P:17C-23C- discussion 38C-40C.
- Gupta S., Leatham E.W., Carrington D. et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction//Circulation. 1997. — Vol. 96. — Vol. 404−407.
- Haider A.W., Larson M.G., Benjamin E.J. et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death // J Am Coii Cardiol. 1998−32 (5):1454−1459.
- Haehling S., Jankowska E.A., Anker S.D. Tumour necrosis factor-alpha and the failing heart: pathophysiology and therapeutic implications // Basic Res Cardiol.- 2004.-Vol.99.-P. 18−28.
- Haller H. Endottielial function: general considerations // Drugs. 1997- 53 (Supp
- Hahn J., Smith J.M. ICD Therapy for the Prevention of Sudden Cardiac Death in Post-MI Patients // Curr. Treat Options Cardiovasc. Med -2003. -Vol.5. -№ 5. -P.369−376.
- Hasdai D., Scheinowitz M., Leibovitz E. Increased serum concentrations of interleukin-ip in patient with coronary artery disease // Heart. 1996. — Vol. 76. -P.24−28.
- Hasper D., Hammel M, Kleber F et al. System inflammation patients with heart failure //Eur. Heart J. 1998, p.761−765.
- HuanLoh P., Windram J. D, Tin L et al. The effects of initiation or continuation of statin therapy on cholesterol level and all-cause mortality, after the diagnosis of left ventricular systolic dysfunction. //Am Heart J.-2007,-Vol. 153(4).-P.537−44.
- Heine U.I., Munoz E. F., Flanders K.C. et al. Colocalization of TGF-beta 1 and collagen I and HI, fibronectin and glycosaminglycans during lung branching morphogenesis // Development.— 1990.— Vol. 109.— P. 2936.
- Heinisch R.H., Zanetti C. R, Comin F. et al. Inflammatory cytokines predicts one-year outcome of patients with acute coronary syndromes but not in stable angina // Eur. Heart J. 2001. -Vol.22, (Suppl).-P.518.
- Heldin C.H., Westmark B. Platelet-derived growth factor mechanism of activation and possible in vivo function // Cell Regulat- 1990.- Vol. 1.-P.555−566.
- Hemler M.E. VLA proteins in the integrin family: structures, functions and their role on leukocytes // Ann. Rev. Immunol.— 1990.— Vol. 8.— P. 365−400.
- Henderson A. Coronary heart disease: overview // Lancet. 1996. — Vol. 348. -P.1−34.
- Hirota H., Izumi M., Hamaguchi T., Sugiyama S. et al. -Circulation interleukin- 6 family cytokines and their receptors in patients with congestive heart. // Heart Vessels.- 2004.-Vol. 19(5).-P.237−41
- Hoffman G., Merkel P., Brassington R. et al. Utility of anti-TNF therapy in Takayasu arteritis. Arthr.Rheum., 2003, v.48, p.5443.
- Hogg K., SwedbergK. Heart Failure with preserved left ventricule systolic function. Epidemiology, Clinical Characteristics, and Prognosis. // J Am CollCardiol. -2004. Vol. 43 (3). -P. 317- 327
- Hosaka K., Ryu J., Saitoh S. et al. The combined effects of anti-TNF-a antibody and IL-1 receptor antagonist in human rheumatoid arthritis synovial membrane // Cytokine, 2005, -v.32, p.263−269.
- Horwich T.B., MacLellan W.R., FonarowG.C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure J Am CollCardiol.- 2004.- P.642−8.
- Horwich T.B., Hamilton M.A., MacLellan W.R., Fonarow G.C. Low serum total between cholesterol and survival in patients with chronic heart failure. J
- Am CollCardiol.- 2003.- Vol. 42.- P.1933−1940. 149.1 <
- Hottman H.M., Fatel D.D. Genomic-based therapy: targeting interleukin-1 for autoinflammatory diseases // Arthr. Rheum., 2004, v.50, p.345−349.
- Hsu H.Y., Wang P.Y., Chen Y.T. et al. Changes in flow-mediated dilatation, cytokines and carotid arterial stenosis during aggressive atorvastatin treatment in normocholesterolemic patients. // J Chin Med Assoc. -2005.-Vol. 68(2).-P.53−8.
- Huang Z., Huang P.L., Panahian N. et al. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase // Science. 1994−265(5180): 18 831 885.
- Ignarro L.J., Cirino G., Casini A. et al. Nitric oxide as a signaling molecule in the vascular system: an overview // J Cardiovasc Pharmacol. 1999- -34(6):879−886.
- Ikeda U., Shimada K. Statins and C-reactive protein // Lancet. 1999.- 353 (9160):1274−1275.
- Ikeda U., Ikeda M., Seino Y. et al. Expression of intercellular adhesion molecule-1 on rat vascular smooth muscle cells by pro-inflammatory cytokines // Atherosclerosis. 1993. -Vol. 104. — P.61−68.
- Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronari Prevention Study (WOSCOPS) // Circulation. 1998- 97(15): 1440−1445
- Ingelsson E., Arnlov J., Lind L., Sundstrom J. Metabolic syndrome and risk for heart failure in middle-aged men Heart. 2006. Vol. 92. P. 1409−1413. 153.
- Ingber D. Mechanical signaling and cellular response to extracellular matrix in angiogenesis and cardiovascular physiology // Circ. Res. 2002 Nov 15−91(10):877−87
- Intengan H.D., Schiffrin E.L. Vascular remodeling in hypertension: roles of apoptosis, inflammation and fibrosis // Hypertension. 2001. N 38. P. 581 587.
- Jack I., Zorgberg G. L, Melt S.S. et al. Statins and the risk of dementia // Lancet 2000- 356: 1627−31.
- Jawien J. New insights into immunological aspects of atherosclerosis // Pol Arch Med Wewn. -2008.-Vol. 118(3).-P. 127−31.
- Jialal I., Stein D., Balis D. et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels // Circulation. 2001- 103 (15): 1933−1935.
- Joukhadar C., Klein N., Prinz M., Schrolnberger C. et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatoryparameters in patients with hypercholesterolemia ThrombHaemost- 2001.-Vol. 85 P.47−51.
- Kalantar-Zadeh K., Block G., Horwich T., Fonarow G.C. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure //J Am CollCardiol. 2004. Vol. 43.- P. 1439−1444.
- Kanda T, Takahashi T. Interleukin-6 and cardiovascular diseases // Jpn Heart J. 2004. Vol.45(2). — P. 183−93.
- Kanda T., Inoue M., Kotajima N. et al. Circulatung interleukin-6 and interieukin-6 receptors in patients with acute and recent myocardial infarction // Circulation. 2000. — Vol.93 .-№ 3. -P. 191−196.
- Kang P. M. Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation / P. M. Kang, A. Haunstetter, H. Aoki // Circ. Res. 2000. — Vol. 87. — P. 118−125.
- Kashiwagi H., Suzuki H. Specific cytokine regulators and their therapeutic potentials — an overview // Internal Med.- 1992: — Vol. 31.- P. 1245−1249.
- Katznelson S., Kobushigava A. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and imniunosuppiession // Kidney Inc 1995- 4S: Suppl 52: 112−5.
- Katznelson S., Wang X.M., Chia O. et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo ana on cytotoxic T-lymphocyte activity in vitro// J Heart Lung Transplant. 1998- 17 (4):335−340.
- Kavanaugh A., Antoni C.E., Gladman D. et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiogiaphic analyses after 1 year. Ann.Rheum.Dis., 2006, v.65, p.1038−1043.
- Kavanaugh A., Tutuncu Z., Sanchez T. The TNF inhibitors in clinical use. // J.Musculoskel.Med., October 2005, suppl, p.29−34.
- Keller R. Immunologic und Immunopathologie. // Theme Verlag, Studgard, Germany, 4ed, 1994. 154 p.
- Kell R., Haunstetter A., Dengler T. J et al. Do cytokines enable risk stratification to be improved in NYHA functional class III patients?
- Comparison with other potential predictors of prognosis. // Eur Heart J.- 2002, -Vol. 23(1). -P.70−8.
- Kent S.M., Flaherty P.J., Coyle L.C., Markwood T.T. Effect of atorvastatin and pravastatin on serum C-reactive protein Am Heart J.- 2003.Vol. 145.-P. 8.
- Kimchi A. Cytokine triggered molecular pathways thar control cell cycle arrest//J. cell. Biochem.—1992.—Vol. 50.—P. 1−9.
- Kimura M, Kurose I, Russell J et al. Effects of fluvastatin on leukocyte-endothelial adhesion hypercholesterolemic rats // Arterioscler Thromb Vase Biol. 1997−17 (S}:1521—1526.
- Kishimoto T. The biology on interleukin 6 // Blood.— 1989.-Vol. 74.-P. 1−10.
- Kita T., Yokode M., Ishii E. et al. The role of oxidized lipoproteins in the pathogenesis of atherosclerosis // Clin Exp Pharmacol Physiol Suppl. 1992−20−37−42.
- Klag M.J. HMG coenzyme A reductase inhibitors: good news and bad news // J Gen Intern Med. 1999−14 (12):777.
- Klagsbrun M. The fibroblast growth factor family: structural and biological properties // Progr. Crowth Factor Res.- 1989.- Vol. 1.- P. 207−226.
- Kleemann R., Zadelaar S., Kooistra T. Cytokines and. atherosclerosis: a comprehensive review of studies in mice. //Cardiovasc Res.- 2008. -Vol. 79(3). -P.360−76.
- Knight C.J. New insights into the pathophysiology of acute coronary occlusion// Eur. Heart J. 1999. — Vol. 1. — P. F3-F6.
- Koenig W. Atherosclerosis involves more than just lipids: focus on inflammation // Eur. Heart Journal. 1999. — Vol. 1. — P. T19-T26.
- Kofoed S.C., Wittrup H.H., Sillesen H. et al. Fibrinogen predicts ischaemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques: the Copenhagen City Heart Study // Eur Heart 1.2003−24 (61:567 576.
- Koh K. Effects of statins on vascular wall: vasomotor function, inflammation and plaque stability.// Cardiovasc.Res.- 2000.-Vol. 47(4).-P. 648
- Koivula M.-K., Aman S., Karjalainen A. et al. Are there autoantibodies reacting against citrullinated peptides derived from type I and type II collagens in patients with rheumatoid arthritis? // Ann. Rheum. Dis., 2005, v.64, p. 1443−1450.
- Kovacs E. J. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue // Immunol. Today.- 1991.- Vol. 12.- P. 17−23.
- Kraehenbuhl J. P., Neutra M. R. Molecular and cellular basis of immune protection of mucosal surfaces // Physiol. Rev.- 1992.- Vol. 72.- P. 853 879.
- Kronke M., Schutze S., Scheurich P. et al. Tumor necrosis factor signal transduction// Cell. Signalling.-1990.- Vol. 2.- P. 1−8.
- Kwak B., Mulhaupt F., Myit S. et al. Statins as newly recognized type of immunomodulator. Nat Med. 2000- 6 (12): 1399−402.
- Kwapisz M. M. The effect of intravenous quinaprilat on plasma cytokines and hemodynamic variables during cardiac surgery // J. Cardiothorac Vase Anesth. 2004. — Vol. 18 (1). — P. 53−58.
- Lacoste L., Lam J.Y., Hung J. Et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction // Circulation. 1995. — Vol. 92. — P. 3172−3177.
- Lagrand W.K., Niessen N.W., Wolbink G.J. et al. C-reactive protein colocalizes with complement in humane hearts during acute myocardial infarction//Circulation. 1997. — Vol.95. — P. 97−103.
- Lasky L.A. The homing receptor (LECAM-l/L-selectin). Adhesion: Its Role in Inflammatory Disease/Eds. J. M. Harlan, D. Y. Liu, — W. H. Freeman.— New York, 1992.
- Latini R., Bianchi M, Correale E. et al. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor and interleukin-1 receptor antagonist // J. Cardiovasc. Pharmacol. -1994.-Vol. 3.-P. 1−6.
- Laufs U., Wassmann S., Hilgers S. et al. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men // J Cardiol.2001−88(l 1): 1306−1307.
- Lawrence M. B., Springer T. A. Leukocyte role on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins // Cell.- 1991.-Vol. 65.- P. 859−873.
- Lee J.-H., Slifman N.R., Gershon S.K. et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor CX antagonists infliximab and etanercept // Arthr. Rheum., 2002, v.46, p.2565−2570.
- Lefer A., Scaha R., Lefer D. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowing: new concepts for cardiovascular disease. // Cardiovascular. Res.- 2001.-Vol 49.-P. 281−287
- Leonardo M.J., Baltimore D. NF-kB: pleiotropic mediator of inducible and tissue-specific gene control // Cell.— 1989: — Vol. 58.— P. 227−229.
- Leppaluoto J., Ruskoalo H. Endothelin peptides: biological activities, celluler signalling and clinical significance//Ann. Med.- 1992.- Vol. 24.-P.153−161.
- Lerman A., Edwards B.S., Kallett J.W. et al. Circulating and tissue endotheiin immunoreactivity in advanced atherosclerosis in humans. // N Engl J Med. 1991−325 (14):997−1001.
- Lerman A., Holmes D., Bell M.R. et al. Endotheiin in coronary endothelial dysfunction and early atherosclerosis in humans // Circulation. 1995- 92 (9):2426−2431.
- Lescovar P., Zanon R., Nachbar F. et al. Die negative rolle von immunkomplexen auf die Immunregulation // Rheuma. 1993. — Vol. 13. -P. 1−7.
- Levin B., Kalman J., Mayer I. Et al. Elevated circulating level of tumor necrosis factor in severe chronic heart failure // N. Engl. J. Med. 1990. -Vol. 223.-P. 236−241.
- Levine J., Hartwell D., Beller D. I. Inbalanced cytokine production by macrophages from autoimmune-prone mice // Immunol. Lett-1991.-Vol.30.- P.183−192.
- Li H., Cybulsky M.I., Gimbrone M.A. et al. An atherogenic diet rapidly induced VCAM-1, a cytokine regulatable mononuclear leukocyte adhesion molecule in rabbit endothelium//Arteriosclerosis Thrombosis. 1993. — Vol. 13. — P. 197−204.
- Libby P., Ridker P.M. Novel inflammatory markers of coronary risk theory versus practice // Circulation. 1999−100 (11):1148−1150.
- Libby P. Atheroma: more than mush // Lancet. 1996. — Vol. 348. — P. 4−7.
- Libby P. Do vascular wall cytokines promote atherogenesis? // Hosp. Pract. -1992.-Vol. 27.- P.51−58.
- Libby P. The molecular bases of the acute coronary syndromes // Circulation. 1995. -Vol. 91. — P. 2844−2850.
- Liebe V. Statin therapy of calcific aortic stenosis: hype or hope? // Eur Heart J 2006- 27:773−776
- Liuzzo G., Biasucci L.M., Gallimore J.R. et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina // N. Engl. J. Med. 1994. — Vol. 331. — P. 417−424.
- Lobb R. R. Integrin-immunoglobulin superfamily interactions in endothelial-leukocyte adhesion. Adhesion: Its Role in Inflammatory Disease // Eds. J. M. Harlan, D. Y: Liu W.H. Freeman.- New York.- 1992.
- Logan A. Intracrine regular at the nucleus a further mechanism growth factor activity? // J.Endocr. — 1990. — Vol.125. — P.339−343.
- Lopez B., Gonzalez A., Vara N. et al. Biochemical assessment of myocardial fibrosis in hypertensive heart disease//Hypertension.-2001.-Vol.38.-№ 5.-P. 1222−1226.
- Lopez B, Querejeta R, Varo N et al. Usefulness of serum carboxy-terminal propeptide of procollagen type 1 in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients // Circulation. 2001,-104(3).-P.286−291.
- Lorenzo E.D., Indorf С., Perrino D., et al. HMG-CoA reductase inhibitors prevent left ventricular hypertrophy by up-regulation of Cdk4 levels // Eur Heart J 2000- 21(Suppl): 261.
- McQueen M.J., Hawken S., Wang X., Ounpuu S. et al. Lipids, lipoproteins and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERFIEART study): acase-controlstuoy //Lancet-2008.-Vol. 372. -№ 9634. -P.224−233.
- Mach F., Schonbeck U., Bonnefoy J.-Y. et al. Activation of monocyte/ macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor // Circulation. 1997. — Vol. 96.- P.396−399.
- Madri J.A., Bell L., Marx M. et al. Effects of soluble factors and extracellular matrix components on vascular cell bejiavior in vitro and in vivo: models of de-endothelization and repair // J. cell. Biochem.- 2001.-Vol. 45, — P. 123−130.
- Maekawa Y, AnzaiT., YoshikawaT. et al. Prognostic significance of periferalmonocytosis after reperfiised acute myocardial infarction: a possible role for left ventricular remodeling // J. Am. Coll. Cardiol.-2002.-Vol.39.-P.241−246.
- Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future Circ Res.- 2002.- Vol. 91.- P.988−98.
- Mann D.L. Recent insights into the role of tumor necrosis factor in failing heart. //Heart Fail. 2001. -Vol.6 (2).- P.71−80
- Mann D.L. Tumor necrosis factor-induced signal transduction and left ventricular remodeling J Card Fail. 2002 -8(6 Suppl):S379−86.
- Marian A.J. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. // Lancet. 2000- 355 (9197):58−60.
- Massague J. Transforming growth factor-alfa. A model for membraneanchored growth factors//J. biol. Chem.- 1990.- Vol. 265.- P. 21 393−21 396.
- Matsumori A., Yamada T., Suzuki H. et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy // British Heart J. 1994. -Vol. 72. -P.561−566.
- Matsushima K., Oppenheim J. J. Review article: interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL-1 and TNF//Cytokine.-1999.-Vol. 1.—P. 2−6.
- Me Murray X, Stewart S. Epidemiology, atiology and prognosis of heart failure // Heart 2000. -Vol.83. -P.596−602.
- Michowitz Y., Arbel Y., Wexler D. et al. Predictive value of high sensitivity CRP in patients with diastoHc heart failure. // ilnt J Cardiol.- 2008.-Vol.l25(3).-P.347−51
- Miyao Y., Yasue H., Ogawa H. et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction // Am. Heart J. 1993. — Vol. 126. — P.1299−1304.
- Modesti P.A., Colella A., Cecioni I. et al. Increased number of thromboxane A2 -prostoglandin H2 platelet receptors in active unstable angina and causative role of enhanced thrombin formation // Am. Heart J.-1995. Vol. 129. — P. 873−879.
- Moreno P.R., Falk E., Palacios I. F et al. Macrophage infiltration in acute coronary syndromes: implication of plaque rupture // Circulation. 1999. -Vol. 90. — P.775−778.
- Mossman T.R. Cytokines: is there bilological meaning? // Curr. Opin. Immunol— 1999.- Vol. 3.-P. 311−314.
- Mozaffarian D., Nye R., Levy W.C. Statin therapy is associated with lower mortality among patients with severe heart failure Am J Cardiol.-2004. -Vol. 93 .-N9.-P.ll 24−9.
- Munger M., Johnson B., Amber I.J. et al. Circulating concentration ofproinflammatory cytokines in the mild or moderate heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy //Am. J. Cardiol. 2006. — Vol. 77. -P.723−727.
- Myers P.R., Parcer J.L., Tanner M.A. et al. Effects of cytokines TNFa and IL-ip on endotoxin-mediated inhibition of endothelium-derived relaxing factor bioactivity and nitric oxide production vascular in endothelium // Shock. 1994. — Vol.1.- P.73−78.
- Nakashima Y., Raines E., Plump A. et al. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse //Art. Thromb. 1998. — Vol. 18. — P.842−851.
- Napoli C., Lerman L.O. Involvement of oxidation-sensitive mechanisms in the cardiovascular effects of hypercholesterolemia // Mayo Clin Proc.2001−76(6} :619−631.
- Nesher N., Frolkis I., Higher levels of serum cytokines and myocardial tissue markers during on-pump versus off-pump coronary artery bypass surgery // J. Card. Surg. -2006. Vol. 21. — P .395−402.
- Negre-Aminoux P., Van Vliet A., van Erck M. et al. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: comparison witn other human cell types // Biochim.- Biophys. Acta. 1997. — Vol.1345.- P.259−268.
- Neri Serneri G.G., Prisco D., Martini F. Et al. Acute T cell activation is detectable in unstable angina // Circulation. 1997. — Vol. 95. — P. 18 061 812.
- Neumann F.J., Ott I., Gawas M. et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction // Circulation. 1995. -Vol. 92 -P.748−755.
- Noll G., Luscher T. F. The endothelium in acute coronary syndromes // Eur Heart Journal. 1998. — Vol. 19. — Suppl. C — P. C30-C38.
- Nordt T.K., Peter K., Ruef J. et al. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost. 1999−82 (Suppl 1): 14−18.
- Okada M., Matsuto T., Miida T. et al. Differences in the effects of cytokines on the expression of adhesion molecules in endothelial cells//Ann. Med. Interne. -1997.-Vol. 148.- P.125−129.
- Olinic D., Anca Cristea, Mirela Stoia et al. Antibodies against oxidized LDL in patients with dyslipidaemia and acute coronary syndromes (Abstr.) // Eur. HeartJ.-1998.-Vol. 19.-P.44.
- Oliver M.F. Cholesterol and strokes. Cholesterol lowering is indicated for strokes due to carotid atheroma. BMJ. 2000−320 i7233}:459−460.
- Opal S.M., De Palo V.A. Antiinflamattory cytokines // Chest. 2000 — Vol. 117(4)-P.l 162−1172
- Owan T.E., Hodge D.O., Herges RM. et al. Trends in prevalence and outcome of heart failure with preserved ejection faction //N. Engl. J. Med. -2006. -Vol.355. -№ 3.-P251−259.
- Parissis J., Venetsanou K., Ziras N et al. Abnormal cytokine expression during the course of acute myocardial infarction (Abstr.) // Eur. Heart J. -1998.-Vol. 19.-P. 508.
- Pasceri V., Chang J., Willerson J.T.et al. Modulation of C-reactive proteinmediated monocyte chemoattractant. Induction in human endothelial cells by antiatherosclerotic drugs//Circulation. 2001- 103 (21):2531−2534.
- Pasceri V., Willerson J.T., Yen E.T. Direct pro inflammatory effect of C-reactive protein on human endothenai // Circulation. 2000- 102(1 S):2165−2168.
- Parission J.T., Fountoulaki K., Paraskevaidis I et al. Depression in chronic heart failure: novel pathophysiological mechanism and therapeutic approaches .//Expert Opinlnvestig Druds. -2005. -Vol 14(5). -P. 567−77
- Penco M., Varveri A., Aurigemma G. Acute and chronic Chlamydiapneumoniae infection in unstable angina (Abstr.) //Eur. Heart J. 1998. -Vol. 19. -P.273.
- Pfeffer M.A., Swedberg K., Granger C.B., Held P. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARMO verallprogramme //Lancet.- 2003.- Vol. 362.- P.759 -766.
- Plehn J.F., Davis B.R., Sacks F.M. et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation. 1999−99 (2):216−223.
- Plenz G., Song Z.F., Tjan T.D. et al. Activation of the cardiac interleukin-6 system in advanced heart failure.//Eur J Heart Fail.- 2001. Vol. 3(4). -P.415−21.
- Plosker G.L., Lyseng-Williav J., MCon K.A. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events // Pharmacoeconomics. 2007.- Vol.25(12).-P.1031−53.
- Pober J.S., Cotran R.S. Cytokines and endothelial cell biology // Physiol. Rev.-1990 b.-Vol. 70.- P. 427−451.
- Pober J.S., Cotran R.S. The role of endothelial cells in inflammation // Transplantation.—1990 a.— Vol. 40 — P. 537−544.
- Prospective Studies Collaborators. Cholesterol, Diastolic blood pressure and stroke: 13 000 strokes in 450 000 pleople in 45 prospective Cohorts // Lancet. 1995−346 (8991−8992):1647−1653.
- Radomsky M., Palmer R., Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets // Br J Pharmacol. 1997- 92. C. l 181−187.
- Rauchhaus M., Doehner W., Francis D.P. et al. Plasma cytokine parameters and mortality in patients with chronic heart failure //Circulation. 2000. Vol. l02.-P.3060−3067.
- Regnstrom J., Nilsson J. Lipid oxidation and inflammation-induced intimal fibrosis //J. Lab. Clin. Med. 1999. -Vol. 116. — P. 162−168.
- Ridker P.M. Intercelluar adhesion molecule (ICAM-1) and the risks of developing atherosclerotic disease // Eur. Heart J. 1998. — Vol. 19. — P. 11 191 121.
- Ridker P.M., Cushman, Stampfer MJ. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men//N. Engl. J. Med. 1997. -Vol. 336.-P.973−979.
- Ridker P.M., Hennekens CH, et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently helthy men //Lancet. -1998. -Vol. 351. P.88−92.
- Ridker P.M., Cushman M., Stampfer M.J. et al. Inflammation, aspirin, and risk of apparently healthy me //N Engi. Mel 1997:336 (14):973−979.
- Ridker P.M., Rifai N., Clearfield M. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events // N Engl J Med. 2001−344 (26): 1959−1965.
- Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 7S in primary hypercholesterolemia // Circulation. 2001:103 (9):1191−1193.
- Ridker P.M., Rifai N., Pfeffer M.A. et al. for Cholesterol and Reccurant Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999- 100 (3):230−235.
- Rifai N., Ridker P.M. High-sensitivity C- reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001:47(31:403−411.
- Rivera M., Talens-Visconti R., Jordan A. et al. Myocardial remodeling and immunologic activation in patients with heart failure. // Rev EspCardiol. 2006- 59(9):911−8.
- Roberts A.B., Sporn M.B. The transforming growth factors-3: Handbookof Experimental Pharmacology, Peptide Growth Factors and Their Receptors // Eds. M.B. Sporn A.B. Roberts.- Heidelberg, Springer-Verlag, 1999.- Vol. 95/1.- P. 419- 472.
- Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction // J.Am. Med. Assoc. -1998. Vol. 279. — P.1643−1650.
- Rosenson R.S., Tangney C.C. Antiatherothrombosis properties of statins: implications for cardiovascular event reduction // JAMA. 1998−279 (20.: 1643−1650.
- Ross R. Atherosclerosis an inflammatory disease // New Engl. J. Med. -1999.-Vol. 340. — P.115−126.
- Ross S.D., Allen E., Connelly J.E. et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med. 1999−159 (15):1793−1802.
- Rubanyi G.M. The role of endothelium in cardiovascular homeostasis and diseases // J. Cardiovasc. Pharmacol. 1999. — Vol. 22. — P. SI -SI 4.
- Rugina M., Caras I., Jurcut R. et al. Systemic inflammatory markers in patients with aortic sclerosis. // Roum Arch Microbiollmmunol. 2007−66(1- i 2): 10−6.
- Sage E.H., Bornstein P. Extracellular proteins that modulate cell-matrix interactions // J.biol. Chem.- 1999.- Vol. 266.- P. 14 831−14 834.
- Rauchhaus M., Doehner W., Francis D.P. et al. Plasma cytokine parameters and mortality in patients with chronic heart failure //Circulation. 2000. Vol.102.-P.3060−3067.
- Satoh M., Nakamura M., Akatsu T. et al. C-reactive protein co-expresses with tumor necrosis factor-alpha in the myocardium in human dilated cardiomyopathy. // Eur J Heart Fail.-2005. Vol. 7(5).- P.748−54.1.V
- Scalia R., Gooszen M.E., Jones S.P. et al. Simvastatin exerts both antiinflammatory and caraicor: E-deficient mice. Circulation. 2001- 103 (21):2598−2603.
- Schattenkichner M., WastlhuberJ., Rau R. et al. Long-term use of the fully human anti-TNF antibody D2E7 in combination with methotrexate in active rheumatoid arthritis. Arthritis Rheum., 2000, v.43, S228.
- Scherer H.U., Burmester G.-R., Riemekasten G. Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis. Ann.Rheum.Dis., 2006, v.65, p. 1245−1247.
- Shlipak M.G., Bibbins-Domingo K. et al. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study // Am J Med. -2008.-Vol.l21(l).-P.50−7.
- Schonbeck U., Mach F., Bonnefoy J.Y. et al. Ligation of CD40 activates interleukin // J. Biol. Chem. 1997. — Vol. 272. — P. 19 569−19 574.
- Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial //JAMA. 2001- 285 (13):1711−1718.
- Schwartzmann S., Flynn T., Barinstein L. et al. Infliximab therapy for resistant uveitis // Arthr.Rheum., 2002, v.46, suppl., S326.
- Sfikakis P.P. Behcet’s disease: a new target for anti-tumor necrosis factor treatment //Ann.Rheum. Dis., 2002, v. 61, suppl. II, p. U51−53.
- Sfikakis P.P., Theodossiadis P.G., Katsiari CO., et al. Effect of infliximab on sight-threatening panuveitis in Behcet’s disease // Lancet, 2001, v.358, p.295−296.
- Shavelle D.M., Takasu J., Budoff M.J. et al. HMG Co A reductase inhibitor (statin) and aortic valve calcium // Lancet 2002- 359(9312): 1125−6.
- Shergy W.J., Cohen S.B., Greenwald M.W., et al. Anakinra (Kineret) inhibits the progression of radiographically measured // Ann.Rheum.Dis., 2002, v.61, suppl. I, p.51.
- Shimizu Y., Shaw S. Lymphocyte interactions with extracellular matrix//FASEB J.-1997.-Vol. 5.- P. 2292−2299.
- Shinohara K., Shoji T., Kimoto E., Yokoyama H. et al. Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus J AtherosclerThromb. 2005.- Vol. 12, — N 4.-P.205−10.
- Sigusch H.H., Lehmann M.H., Reinhardt D. et al. Chemotactic activity of serum obtained from patients with idiopathic dilated cardiomyopathy // Pharmazie.- 2006. Vol.61 (8). — P. 706−9.
- Simon E., McDonald J.A. Extracellular matrix receptors in the kidney cortex //Amer. J. Physiol.— 1998.— Vol. 259.— P. F783-F792.
- Simone A.D., Yazdani S., Wang W. Circulating levels of IL-l?, a prothrombotic cytokine, are elevated in unstable angina versus stable angina //J. Thromb.Thrombolysis.-2000.-VoL9(3).-P.217−222
- Sola S., Mir M.Q., Lerakis S. et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure // AmCollCardiol. -2006.-Vol. 47(2).-P.332−7.
- Soma M.R., Donetti E., Parolini N. et al. HMG CoA reductase inhibitors, in vivo effects on carotid intimal thickening in normocholesterolemic rabbits // Arterioscler Thromb. 1993−13 (4):571−578.
- Souza K.L., Gurgul-Convey E., Eisner M., Lenzen S. Interaction between pro-inflammatory and anti-inflammatory cytokines in insulin-producing cells. //J Endocrinol.-2008.-VoLl97(1).-P. 139−50.
- Spencer F.A., Allegrone X., Goldberg R.X. et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study // Ann Intern. Med-2004. Vol. 140. — №. 11. -P.857−866.
- Spinale F. Matrix metalloproteinases: regulation and dysregulation in the tailing heart // Circ. Res. -2002. -Vol. 90. -№ 5. -P.520−530.
- Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. 1999, Cell 76 (2):301−314.
- Stefanadis C., Toutouzas K., Vavuranakis M. et al. Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques//Eur Heart J. 2002−23 (21):!664−1669.
- Stenvinkel P., Barany P., Heimbtirger O. et al. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? //Kidney Int Suppl.-2002.-Vol.80.-P. 103−8.
- Stoll L.L., Denning G.M., Weintraub N.L. Potential Role of Endotoxin as a Proinflammatory Mediator of Atherosclerosis ArteriosclerThromb Vase Biol.-2004.- Vol. 24.- P.2227−2236.
- Stumpf С., Petzi S., Seybold К. et al. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction // ClinSci (Lond). -2008. May 6. Epub ahead of print.
- Suzumura K., Yasuhara M., Janaka E. et al. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor // Chem Pharm Bull (Tokyo). 1999−47 (7): 1010−1012
- Suzuki H., Sato R., Sato T. et al. Time-course of changes in the levels of interleukin- 6 in acutely decompensated heart failure. //Int J Cardiol.-2005.-Vol.l00(3).-P.415−20.
- Tannous M., Cheung R., Vignmi A. et al. Atorvastatin increases ecNOS levels in human platelets of hyperiipidemic subjects // Thromb Haemost. 1999−82(5): 1390−1394.
- Tatli E., Kurum T. A controlled study of the effects of Carvedilol on clinical events, left ventricular fimction and proinflammatory cytokines levels in patients with dilated cardiomyopathy // Can J Cardiol 2005- 21(4):344−8.
- Tedqui A., Bernard C. Cytokines, immuno-inflammatory response and atherosclerosis //Eur. Cytokine Netw. -1994. Vol. 5. — P.263−270.
- Timonen P., Magga J., Risteli J. et al. Cytokines, interstitial collagen and ventricular remodelhng in dilated cardiomyopathy ./Ant J Cardiol. 2008. Vol. 124(3).-P.293−300.
- Togersen A.M., Jansson J.H., Boman K. et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women // Circulation. 1998. — Vol. 98. -P.2241−2247.
- Torre-Amione G. Immune activation in chronic heart failure.//Am J Cardiol. 2005 Jun 6- 95 (UA): 38C-40C.
- Thorne S.A., Abbot S.E., Stevens C.R. Modified low density lipoprotein and cytokines mediate monocyte adhesion to smooth muscl cells // Atherosclerosis. -1996.-Vol. 127.-P. 167−176.
- Tomas M., Senti M., Garcia-Fana F. et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vase Biol. 2000−20(9):2113−2119.
- Tomiyama H., Yamashina A., Arai T., et al: Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement—a survey of 12 517 subjects // Atherosclerosis.- 2003.- Vol. 166.- P.303−309.
- Treasure C.B., Klein J.L., Weintraub W.S. et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease //N. Engl. J. Med. 1999. -Vol. 332. -P. 481−487.
- Trip M.D., Cats V.M., van Capelle F.J.L. et al. // Platelet hyper-reactivity and prognosis in survivors of myocardial infarction // N. Engl. J. Med.1999. Vol. 322. — 1549−1554.
- Tsunekawa T., Hayashi T., Kano H. et ai. Cerivastatin, a hydroxymethyigiutaryi coenzyme a reductase inhibitor, improved endothelial function in elderly diabetic patients within 3 days. // Circulation. 2001- 104 (4):376−379.
- Uno H., Ueki Y., Murashima J. tt al. Removal of LDL from plasma by adsorption reduces adhesion molecules on mononuclear cells in patients with arteriosclerosis obliterans // Atherosclerosis. 1999. — Vol. 116. — P. 93−102.
- Valantinc N.A., Schoeder J.S. HMG-Co A reductase inhibitors reduce transplant coronary artery disease and mortality. Evidence for antigen-independent mechanism// Circulation. 1997- 96(5):p. 1370−1373.
- Vallance P., Collier J., Bhagat K. Infection, inflammation and infarction: does acute endothelial dysfunction provide a link? // Lancet. 1997. — Vol. 349. — P.1391−1392.
- Van der Wai A.C., Piec J.J., de Boer O.J. et al. Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes//Heart. 1998. -Vol. 80. — P.14−18.
- Van Seventer G.A., Shimizu Y., Shaw S. Roles of multiple accessory molecules in T-cell activation // Curr. Opin. Immunol.- 1998.- Vol. 3.-P.294−303.
- Varo N., Iraburu M., Varela M. et al. Chronic AT (I) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypersensitive rats // Hypertension 2000−35(6):1197:1202
- Vassali J.D., Sappino A. P., Belin D. The plasminogen activator/plasmin system//J. clin. Invest.- 1999.- Vol. 86.- P. 1067−1072.
- Vaughan C.I. Vascular effects of statins in stroke // Stroke. 1997−28 (111:2315−2320.
- Vollenhoven van R., Harju A., Bratt J. et al. Etanercept and infliximab treatment in Stockholm TNF-C4 antagonist registry: a comparison of two TNF-a antagonists. Ann. Rheum. Dis., 2001, v.44, suppl, S79.
- Wagner A.H., Kohler T., Ruckschloss U. et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation // Arterioscler Thromb Vase Biol. 2000−20 (11:61−69.
- Walter D.H., Fichtlscherer S., Sellwig M. et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol. 2001 -37 (3):839−846.
- Wang P., Ba Z.E., Chaudry I.H. Administration of tumor necrosis factor-. alpha in vivo depresses endothelium-dependent relaxation // Am. J. Physiol.- 1998. -Vol. 266.-P. H2535-H2541.
- Warshafsky S., Packard D., Marks S. etal. Efficacy of 3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke. J Gen Intern Med. 1999,14 (12):763−774.
- Watson K.D., Dixon W.G., Hyrich K.L. et al. Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis. // Ann.Rheum.Dis., 2006, v.65, p.512.
- Weber N., Erl W., Weber K.S.et al. HMG-CoA reductase inhibitors decrease CDllb expression and CDllb dependent adhesion of monocytesto endothelium and reduce increased adhesiveness of monocytes // J Am Coll Cardiol. 1997- 30. 51:1212−1217.
- Weis M., Heeschen C., Glassford AJ. et al. Statins have biphasic effects onangiogenesis // Circulation. 2002- 105 (6):739−745.
- Weissberg P.L. Atherosclerosis involves more than just lipids: plaque dynamics //Eur. Heart J. 1999. — Vol. 1. — P. T13-T18.
- Weissberg P.L. Clesham G., Bennet M. Is vascular smooth muscle cell proliferation beneficial? // Lancet. 1996. — Vol. 347. — P.305−307.
- Wei M., Kuukasjarv P. Cytokine responses and myocardial injury in coronary artery bypass grafting // Scand. J. Clin. Lab. Invest. 2001. -Vol. 61 (2) .-P. 161−166.
- Wei M., Kuukasjarvi P., Laurikka J. et al. Imbalance of pro- and antiinflammatory cytokine responses in elderly patients after coronary artery bypass grafting // Aging ClinExp Res. 2003. — Vol. 15 (6). — P. 469−474.
- Wei M., Kuukasjarvi P. Relation of cytokines to vasodilation after coronary artery bypass grafting // World J. Surg. 2003 — Vol. 27 (10). — P. 1093−1098.
- Westerberg M., Bengtsson A., Ricksten A. et al. Tumor necrosis factor gene polymorphisms and inflammatory response in coronary artery bypass grafting patients // ScandCardiovasc J. 2004. — Vol. 38 (5). — P. 312−317.
- Whalley G.A., Gamble G D, Doughty RN. Restrictive diastolic filling predicts death after acute myocardial infarction: systematic review and metaanalysis of prospective studies // Heart -2006.-Vol.92.-P. 1588−1594.
- Widmer A., Linka AZ., AttenhoferJost C.H., et al. Mechanical complications after myocardial infarction reliably predicted using C-reactive protein levels and lymphocytopenia// Cardiolog. -2003. Vol.99.-№l. -25−31.
- Wiklund O., Mattsson-Hulten L., Hurt-Camejo E., Oscarsson J. Effects of simvastatin and atorvastatin on inflammation markers in plasma //J Intern Med. 2002.- Vol. 251.- P.338−47.
- Williams L.T. Signal transduction by the platelet derived growth factor receptor//Science.-1999.—Vol. 243.—P. 1564−1570.
- Yamauchi-Takihara K., Cara Y., Ogata A. et al. Hypoxic stress inducesj>50cardiac myocyte-derived interleukin-6 // Circulation. 1995. — Vol. 91. -P. 1520−1524.
- Yin W.H., Chen J.W., Jen H.L. et al. The prognostic value of circulating soluble cell adhesion molecules in patient with chronic congestive heart failure // Eur J Heart Fail. 2003−5 (4):507−516.
- Yoshida M., SawadaT., Ishii H. HMG-CoA reductase inhibitor modulates monocyte-endothelial cell integrator under pnystological flow condition in vitro: involvement of Rho GTPase-dependent mechanism // Arterioscler Thromb Vase boil.2001,21,7:1165— 1171.
- Yoshizumi M., Perella M.A., Burnett J.C. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life // Circ. Res. 1998. -Vol. 73. — P.205−209.
- Zeiher A.M., Drexler H., Wollschlager H. et al. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis // Circulation. 1999. -Vol. 83. — P.391−401.
- Zhou X., Stemme S., Hansson GK. Evidence for a local immune response in atherosclerosis. CD4+T cells infiltrate lesions of apolipoprotein-E-deficient mice // American Journal of Pathology. 1996. — Vol.149. — P.359−3 66.
- Zimmerman G. A., Mclntyre T. M., Mehra M., Prescott S. M. Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion//Cell Biol.— 1996.—Vol. 110.—P. 528−540.
- Zureik M., Bureau J.M., Temmar M., et al: Echogenic carotid plaques are associated with aortic arterial stiffness in subjects with subclinical carotid atherosclerosis // Hypertension.-2003.- Vol.41. P.519−527.